MedicBK
MedicBK
partnership
with pharmaceutical companies
with pharmaceutical companies
Connecting doctors and pharmaceutical companies on MedicBK platforms “Training simulator" & “CDSS". 1 doctor – more than 2 views per month
A native way to differentiate among drugs in forecasted outcomes
Supporting doctors regarding your drug products
Targeted communication of pharma representatives with doctors regarding drug choices for any chosen clinical case
Organic growth of targeted audience with MedicBK referential program
Access to unique statistics: frequency and dynamic of drug choice, clinical cases database, CPG adherence
Sponsoring clinicians' access
Requesting registry data analysis from healthcare providers
Requesting registry data analysis from healthcare providers
Combination of our services provides a tool for a conscious therapy choice
Members of professional associations
access to MedicBK
Pharmaceutical companies' medical audience
using widgets to access MedicBK from any website
Brand and
drug placement
drug placement
displaying a sponsored drug when a specific INN is chosen; a transition to a sponsor's website
Analysis report of healthcare registries
objective reports of healthcare drugs procurement and doctors training
Nosological profiles and partnership stages
1
Cardiology
Arterial hypertension
Atrial fibrillation
CHF and CHD
2
Oncology: Breast Cancer & NSCLC
Conducting a clinical trial
Doctors and specialists access
Doctors and specialists access
3
Start of a partnership, access to a medical consultant
Adding clinical cases
Service integration
Refferal program
Service integration
Refferal program
4
The main stage (6+ months)
SMM support
Achieving KPI
Achieving KPI
INTELLIGENCE research outcomes showed a significant impact of MedicBK on treatment tactics that led to forecast outcomes improvement
A retrospective assessment of the adequacy of treatment choice in patients made by MedicBK, National Medical Research Centre NA Almazov, 2020
ClinicalTrials.gov Identifier: NCT04564118
291 patients took part in the research
2560 - total number of patients with these diagnoses in 2019, Almazov EHR; 20% – inpatient, 80% – outpatient
Audition of Almazov CPG adherence
Registry evaluation of Antihypertensive, Anticoagulant and Antiarrhythmic therapy in MedicBK program
Prescriptions made by Almazov centre experts with the use of MedicBK services
Prescriptions were based on the key patients’ characteristics from EHR, previous prescriptions were blinded
92% of the initial treatments adhered to CPG
77% of drugs/interventions were changed in relation to initial prescriptions
14 - an average amount of therapeutic combinations available for arterial hypertension (2-36 for every patient), the total amount of INN - 42
31% more drugs were prescribed (that improved an overall CPG adherence)
31% more drugs were prescribed (that improved an overall CPG adherence)
For further information please contact our CEO
For further information please contact our CEO
e-mail: konarm@medicbk.com
Alexander Romanov
MD PhD FESC FHRS FEHRA
Denis Losik
MD PhD Silver member EHRA and Heart Failure
Dmitry Ponomarev
MD PhD MSc in Biostatistics, fellow in guideline methodology of the European Respiratory Society
Konstantin Armyanov
CEO MedicBK
Entrepreneur
Entrepreneur
Alexei Penskhih
CTO MedicBK
IT-engineer
IT-engineer
Valeriya Zaytseva
Marketing Manager
MedicBK
MedicBK
